More than a dozen lawsuits have been filed on behalf of weight-loss drug users who claim that popular weight-loss medications such as Ozempic have caused a loss of vision.
Patients from New York and New Jersey have claimed that they suffered non-arteritic anterior ischemic optic neuropathy after taking drugs containing semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus. The condition is rare and includes a loss of blood flow to the optic nerve that causes sudden vision loss in one eye.
"People are just waking up and developing this [vision] condition,” Jason Goldstein, the lawyer representing the patients, told Newsday. “They wake and they totally can't see. A lot of them lose their peripheral vision. They could lose total vision. I have one client who lost it in both eyes."
One of the patients, 57-year-old Edward Fanelli, told the newspaper, "If it was on the label, I definitely wouldn't have taken it,” referring to a warning of potential vision loss.
Fanelli, a New Jersey resident, started taking Ozempic to treat his Type 2 diabetes in October 2022 and was diagnosed with the condition about eight months later. He could no longer do his job as a general contractor because of his vision loss.
Novo Nordisk, the maker of Ozempic and Wegovy, has defended its popular medications. Lauren Browdy Weiner, a spokesperson for the drug maker, said the condition is not considered a possible adverse reaction for drugs.
"Novo Nordisk is of the opinion that the benefit-risk profile of semaglutide remains unchanged,” she told Newsday.
She continued: “Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from use of our medicines very seriously.
“This also relates to eye conditions, which are well-known comorbidities for people living with diabetes."
Source: The Independent, 20 May 2025
Recommended Comments
Create an account or sign in to comment